CERS · Cerus Corporation
AI read · Good for CERS
The AI's read
This could let Cerus use its blood-safety technology in more red-cell transfusions. The company kept its 2026 sales forecast at $229 million to $231 million, and its new kit-selling approach increased sales volume and the share left after product costs. Management cited economic and geopolitical challenges, but also reported 10 straight quarters of positive results on its adjusted profit measure.